Literature DB >> 20848150

Risk factors and outcomes of Escherichia coli bacteremia caused by strains that produce CTX-M or non-CTX-M extended-spectrum-beta-lactamases.

U-I Wu1, J-L Wang, W-C Chen, S-C Chang, Y-C Chen.   

Abstract

To determine whether there are differences in risk factors and outcomes among patients with E. coli bacteremia caused by strains that produce CTX-M or non-CTX-M extended-spectrum beta-lactamases. From 1 July 2005 to 30 June 2007, patients with positive blood culture of extended-spectrum β-lactamases (ESBL)-producing E. coli were reviewed. Sixty patients with ESBL-producing E. coli bacteremia were identified. These included 41 (68.3%) isolates with CTX-M β-lactamases. CTX-M-14 accounted for 31 (75.6%) and CTX-M-3 for 9 (22.0%) of the 41 CTX-M isolates. Patients with CTX-M strains were less likely, by univariate analysis, to have significant risk factors for infection including age ≥ 65 years, chronic renal insufficiency, ICU stay at bacteremia onset, central venous catheter use and mechanical ventilation. Multivariate analysis revealed that chronic renal failure and ICU stay were independent predictors. Antibiograms were similar for CTX-M and non-CTX-M producers except that CTX-M strains were significantly more susceptible to cefmetazole (92.7 vs 36.8%, p < 0.0001). The overall mortality and length of hospitalization were not significantly different between the two groups. E. coli with CTX-M β-lactamases was more likely than non-CTX-M strains to invade non-compromised patients. There were no differences in clinical outcomes between the two groups.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848150     DOI: 10.1007/s10096-010-1048-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  26 in total

1.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 2.  The CTX-M beta-lactamase pandemic.

Authors:  Rafael Cantón; Teresa M Coque
Journal:  Curr Opin Microbiol       Date:  2006-08-30       Impact factor: 7.934

3.  CTX-M beta-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors.

Authors:  Jean-Philippe Lavigne; Hélène Marchandin; Julien Delmas; Jérôme Moreau; Nicole Bouziges; Evelyne Lecaillon; Laurent Cavalie; Hélène Jean-Pierre; Richard Bonnet; Albert Sotto
Journal:  J Clin Microbiol       Date:  2006-11-15       Impact factor: 5.948

4.  Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Jesús Rodríguez-Baño; Juan C Alcalá; Jose M Cisneros; Fabio Grill; Antonio Oliver; Juan P Horcajada; Teresa Tórtola; Beatriz Mirelis; Gemma Navarro; María Cuenca; María Esteve; Carmen Peña; Ana C Llanos; Rafael Cantón; Alvaro Pascual
Journal:  Arch Intern Med       Date:  2008-09-22

5.  Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia.

Authors:  Yardena Siegman-Igra; Boaz Fourer; Ruth Orni-Wasserlauf; Yoav Golan; Aliza Noy; David Schwartz; Michael Giladi
Journal:  Clin Infect Dis       Date:  2002-04-30       Impact factor: 9.079

6.  Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection.

Authors:  Timothy S Naimi; Kathleen H LeDell; Kathryn Como-Sabetti; Stephanie M Borchardt; David J Boxrud; Jerome Etienne; Susan K Johnson; Francois Vandenesch; Scott Fridkin; Carol O'Boyle; Richard N Danila; Ruth Lynfield
Journal:  JAMA       Date:  2003-12-10       Impact factor: 56.272

7.  Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.

Authors:  N Woodford; M E Ward; M E Kaufmann; J Turton; E J Fagan; D James; A P Johnson; R Pike; M Warner; T Cheasty; A Pearson; S Harry; J B Leach; A Loughrey; J A Lowes; R E Warren; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2004-09-03       Impact factor: 5.790

8.  Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes.

Authors:  Johann D D Pitout; Nancy D Hanson; Deirdre L Church; Kevin B Laupland
Journal:  Clin Infect Dis       Date:  2004-05-25       Impact factor: 9.079

9.  CTX-M type beta-lactamases among fecal Escherichia coli and Klebsiella pneumoniae isolates in non-hospitalized children and adults.

Authors:  Pak-Leung Ho; River Chun-Wai Wong; Kin-Hung Chow; Kenneth Yip; Samson Sai-Yin Wong; Tak-Lun Que
Journal:  J Microbiol Immunol Infect       Date:  2008-10       Impact factor: 4.399

10.  Genetic background of Escherichia coli and extended-spectrum beta-lactamase type.

Authors:  Catherine Branger; Oana Zamfir; Sabine Geoffroy; Geneviève Laurans; Guillaume Arlet; Hoang Vu Thien; Stéphanie Gouriou; Bertrand Picard; Erick Denamur
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

View more
  7 in total

1.  Clinical significance of infections caused by plasmid-mediated AmpC β-lactamases and extended-spectrum β-lactamase-producing Escherichia coli.

Authors:  H S Cheong; K S Ko; C-I Kang; D R Chung; K R Peck; J-H Song
Journal:  Infection       Date:  2012-09-27       Impact factor: 3.553

2.  Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.

Authors:  Jennifer H Han; Kei Kasahara; Paul H Edelstein; Warren B Bilker; Ebbing Lautenbach
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

3.  Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies.

Authors:  Patricia Cornejo-Juárez; Juan Antonio Suárez-Cuenca; Patricia Volkow-Fernández; Jesús Silva-Sánchez; Humberto Barrios-Camacho; Esmeralda Nájera-León; Consuelo Velázquez-Acosta; Diana Vilar-Compte
Journal:  Support Care Cancer       Date:  2015-05-27       Impact factor: 3.603

4.  Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical Center.

Authors:  Kayoko Hayakawa; Sureka Gattu; Dror Marchaim; Ashish Bhargava; Mohan Palla; Khaled Alshabani; Uma Mahesh Gudur; Harish Pulluru; Pradeep Bathina; Pranathi Rao Sundaragiri; Moumita Sarkar; Hari Kakarlapudi; Balaji Ramasamy; Priyanka Nanjireddy; Shah Mohin; Meenakshi Dasagi; Satya Datla; Vamsi Kuchipudi; Swetha Reddy; Shobha Shahani; Vijaya Upputuri; Satya Marrey; Vedavyas Gannamani; Nandhini Madhanagopal; Srinadh Annangi; Busani Sudha; Kalyan Srinivas Muppavarapu; Judy A Moshos; Paul R Lephart; Jason M Pogue; Karen Bush; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

5.  Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies.

Authors:  Patricia Cornejo-Juárez; Carolina Pérez-Jiménez; Jesús Silva-Sánchez; Consuelo Velázquez-Acosta; Fernanda González-Lara; Fernando Reyna-Flores; Alejandro Sánchez-Pérez; Patricia Volkow-Fernández
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

6.  First multicenter study on multidrug resistant bacteria carriage in Chinese ICUs.

Authors:  Xiaojun Ma; Yinghong Wu; Liuyi Li; Qian Xu; Bijie Hu; Yuxing Ni; Anhua Wu; Shumei Sun; Vincent Jarlier; Jérôme Robert
Journal:  BMC Infect Dis       Date:  2015-08-21       Impact factor: 3.090

7.  No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia.

Authors:  Shi Thong Heng; Swaine L Chen; Joshua G X Wong; David C Lye; Tat Ming Ng
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.